NEVVI Medicare utilization intelligence

← back

KING, DAVIDM.D. NPI 1417049396 Clinician

Medical Oncology · FRIDLEY, MN

Specialty Medical Oncology — from billed Medicare claims
Trained UNIVERSITY OF COLORADO SCHOOL OF MEDICINE, DENVER — medical school, self-reported to CMS
In practice about 33 years since medical school (class of 1993, self-reported to CMS)
Location FRIDLEY, MN · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 55 codes billed · 94,562 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
MINNESOTA ONCOLOGY HEMATOLOGY PA
2019–2026
NOVACARE OUTPATIENT REHABILITATION EAST, INC.
2025

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2018-02

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9299 Injection, nivolumab, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0185 Injection, aprepitant, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80053 Blood test, comprehensive group of blood chemicals
83615 Lactate dehydrogenase (enzyme) level
J2469 Injection, palonosetron hcl, 25 mcg
36415 Insertion of needle into vein for collection of blood sample
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96375 Injection of additional new drug or substance into vein
82784 Gammaglobulin (immune system protein) measurement
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
96372 Injection of drug or substance under skin or into muscle
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J3489 Injection, zoledronic acid, 1 mg
84443 Blood test, thyroid stimulating hormone (tsh)
86334 Immunologic analysis technique on serum (immunofixation)
82378 Carcinoembryonic antigen (cea) protein level
83521 Measurement of immunoglobulin light chains
84153 Psa (prostate specific antigen) measurement, total
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
85046 Red blood count automated, with additional calculations
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
83735 Magnesium level
96417 Administration of additional new drug or substance into vein, 1 hour or less
84439 Thyroxine (thyroid chemical), free
96361 Infusion into a vein for hydration, each additional hour
J7030 Infusion, normal saline solution , 1000 cc
82607 Cyanocobalamin (vitamin b-12) level
81002 Urinalysis, manual test
84165 Protein measurement, serum
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
82746 Folic acid level, serum
96415 Administration of chemotherapy into vein, each additional hour
96360 Infusion into a vein for hydration, 31-60 minutes
82565 Blood creatinine level
96374 Injection of drug or substance into vein
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
86140 Measurement c-reactive protein for detection of infection or inflammation
96523 Irrigation of implanted venous access drug delivery device

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.